EUVIMEDEUVIMED entdecken
Vergleichsstudie

Real-World Use and Outcomes of Lung-RADS v1.1 Category 4B Versus Lung-RADS v2022 Category 0 for Suspected Infectious or Inflammatory Findings on Lung Cancer Screening CT

Silvia Arora, Mark M Hammer, Suzanne C Byrne

American Journal of Roentgenology · 2025

DOI: 10.2214/ajr.25.33279 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift American Journal of Roentgenology, 2025. Verfasst von Silvia Arora und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. Hauptthemen laut MEDLINE: Lung Neoplasms, Early Detection of Cancer, Tomography, X-Ray Computed, Respiratory Tract Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND. Lung-RADS version 2022 (v2022) updated the reporting of suspected infectious/inflammatory findings warranting short-term follow-up, replacing the option in Lung-RADS version 1.1 (v1.1) to classify such findings as Lung-RADS category 4B with an option to classify such findings as Lung-RADS category 0. OBJECTIVE. The purpose of this study was to compare real-world use and outcomes of Lung-RADS v1.1 category 4B and Lung-RADS v2022 category 0 for suspected infectious/inflammatory findings on lung cancer screening (LCS) examinations. METHODS. This retrospective study included 14,478 patients (mean age, 63.2 ± 7.0 [SD] years; 7801 men, 6677 women) who underwent LCS CT from January 2019 to December 2023, interpreted using either v1.1 or v2022. Radiology reports were reviewed to identify examinations reported as Lung-RADS 4B using v1.1 or Lung-RADS 0 using v2022 due to suspected infectious/inflammatory findings and to characterize primary findings. Cases were classified as benign or malignant on the basis of EMR data and follow-up imaging. Examinations classified as Lung-RADS 4B and Lung-RADS 0 were compared. RESULTS. The frequency of Lung-RADS 4B classification due to suspected infectious/inflammatory findings using v1.1 was 0.4% (55/14,478) and Lung-RADS 0 classification due to suspected infectious/inflammatory findings using v2022 was 0.8% (88/11,348) (p < .001). The primary findings for Lung-RADS 4B examinations were most commonly solid nodule (65%) or part-solid nodule (24%) and for Lung-RADS 0 examinations were most commonly ground-glass nodule/opacity (43%), solid nodule (25%), or tree-in-bud nodules (13%) (p < .001). Of Lung-RADS 4B examinations, 76% were benign, 22% were malignant, and 2% had insufficient follow-up; of Lung-RADS 0 examinations, 98% were benign, none were malignant, and 2% had insufficient follow-up (p < .001). No examination with a primary finding of ground-glass nodule/opacity or tree-in-bud nodules was malignant. CONCLUSION. For suspected infectious/inflammatory findings, Lung-RADS 0 for v2022 was used more frequently than Lung-RADS 4B for v1.1. However, no Lung-RADS 0 examination was malignant. Lung-RADS 0 designations were commonly for findings (i.e., ground-glass or tree-in-bud nodules) for which v2022 indicates short-term follow-up may not be warranted. CLINICAL IMPACT. Adherence to Lung-RADS guidance regarding types of suspected infectious/inflammatory findings warranting Lung-RADS 0 classification is important for avoiding potentially unnecessary follow-up recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsEarly Detection of CancerTomography, X-Ray ComputedRespiratory Tract InfectionsRadiology Information SystemsRetrospective StudiesHumansMaleFemaleMiddle AgedAgedReproducibility of ResultsLungPneumonia

Stichwörter der Autor:innen

infectiousinflammatorylungmalignancyscreening

Autor:innen und Institutionen

  • Department of Radiology, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115.
  • Department of Radiology, Harvard Medical School, Boston, MA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Arora, S., Hammer, M. M., & Byrne, S. C. (2025). Real-World Use and Outcomes of Lung-RADS v1.1 Category 4B Versus Lung-RADS v2022 Category 0 for Suspected Infectious or Inflammatory Findings on Lung Cancer Screening CT. American Journal of Roentgenology. https://doi.org/10.2214/ajr.25.33279

Vancouver

Arora S, Hammer MM, Byrne SC. Real-World Use and Outcomes of Lung-RADS v1.1 Category 4B Versus Lung-RADS v2022 Category 0 for Suspected Infectious or Inflammatory Findings on Lung Cancer Screening CT. American Journal of Roentgenology. 2025. doi:10.2214/ajr.25.33279

BibTeX
@article{Arora2025,
  author = {Arora, Silvia and Hammer, Mark M and Byrne, Suzanne C},
  title = {Real-World Use and Outcomes of Lung-RADS v1.1 Category 4B Versus Lung-RADS v2022 Category 0 for Suspected Infectious or Inflammatory Findings on Lung Cancer Screening CT},
  journal = {American Journal of Roentgenology},
  year = {2025},
  doi = {10.2214/ajr.25.33279}
}
Kostenlos starten →